Effect of sacubitril/valsartan on endothelial dysfunction and arterial stiffness in patients with chronic heart failure

29 August 2022 (16:20 - 16:30)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Velia Cassano

Magna Graecia University of Catanzaro, Catanzaro (Italy)

5 More presentations in this session

Presentation thumbnail

Effects of sacubitril-valsartan on clinical, echocardiographic and polygraphic parameters in patients affected by heart failure with reduced ejection fraction and sleep apnea

Doctor G. Armentaro (Catanzaro, IT)

Abstract Slides Video

Presentation thumbnail

Sacubitril/valsartan compared to ramipril in high risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial

Professor M. Schou (Gentofte, DK)

Abstract Slides Video

Presentation thumbnail

ARNI effects in HFrEF. Risk reduction beyond LVEF

Doctor A. Boehmer (Wiesbaden, DE)

Abstract Slides Video

Presentation thumbnail

Prevalent and incident anaemia in PARADIGM-HF and effect of sacubitril/valsartan

Doctor J. Curtain (Dublin, IE)

Abstract Slides Video

Presentation thumbnail

Effects of angiotensin receptor-neprilysin inhibitors (ARNIs) on the glucose and fat metabolism biomarkers leptin and fructosamin

Doctor B. Ohnewein (Salzburg, AT)

Abstract Slides Video

Access the full session

Session thumbnail

Neprilysin inhibition: news and nuggets

The Event

Event poster

ESC Congress 2022

29 August 2022 16:20 CET

You may be interested in

Congress Session

Heart failure due to hypertension: innovative drug and device-based therapies

Congress Session

Hypertension and heart failure: a dangerous crossroads

Congress Presentation

Treatment with sacubitril/valsartan and improvement of ventricular-arterial coupling in heart failure with reduced ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources